TREO 腹部覆膜支架系统的批准后研究 (TREO PAS)
TREO 腹主动脉支架系统 (P190015) 在肾下腹主动脉瘤和主髂动脉瘤患者中的批准后研究
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
研究概览
详细说明
This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.
The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- Vascular Surgery Specialists
-
Tucson、Arizona、美国、85718
- Pima Heart and Vascular
-
-
California
-
Fresno、California、美国、93701
- University of California, San Francisco-Fresno
-
La Jolla、California、美国、92037
- University of California, San Diego
-
San Diego、California、美国、92161
- VA San Diego
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Anschutz
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale University
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- Medstar Washington Hospital Center
-
-
Florida
-
Gainesville、Florida、美国、32610
- University of Florida
-
Gainesville、Florida、美国、32608
- Malcom Randall VA Medical Center
-
Pensacola、Florida、美国、32504
- Coastal Vascular and Interventional
-
Tampa、Florida、美国、33606
- University of South Florida / Tampa General Hospital
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- Northside Hospital
-
Atlanta、Georgia、美国、30309
- Piedmont Heart Institute
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
Boston、Massachusetts、美国、02111
- Tufts Medical Center
-
-
Michigan
-
Bay City、Michigan、美国、48708
- McLaren Bay Region
-
Detroit、Michigan、美国、48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Barnes Jewish Hospital at Washington University
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
New Brunswick、New Jersey、美国、08901
- Rutgers Robert Wood Johnson Medical Center
-
-
New York
-
New York、New York、美国、10075
- Lenox Hill Hospital / Northwell Health
-
Stony Brook、New York、美国、11794-8191
- Stony Brook Medical Center
-
Syracuse、New York、美国、13210
- SUNY Upstate Medical University
-
The Bronx、New York、美国、10467
- Montefiore Medical Center
-
-
North Carolina
-
Asheville、North Carolina、美国、27607
- Mission Health
-
Greenville、North Carolina、美国、27834
- East Carolina University
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health and Science University
-
Portland、Oregon、美国、97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19140
- Temple University Hospital
-
Pittsburgh、Pennsylvania、美国、15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Kingsport、Tennessee、美国、37660
- Wellmont Cardiology Services
-
-
Texas
-
Austin、Texas、美国、78756
- St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- University of Utah Hospital
-
-
Virginia
-
Norfolk、Virginia、美国、22042
- Sentara Heart Hospital
-
Richmond、Virginia、美国、23282
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Medical College of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Willing and able to comply with all study procedures and visits.
- Written informed consent to participate in the study.
- Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
- Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.
Exclusion Criteria:
• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Subjects who receive the TREO Abdominal Stent-Graft System
Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System. |
The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
大体时间:Through 5 Years post-procedure
|
Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies. |
Through 5 Years post-procedure
|
|
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
大体时间:Through 5 Years post-procedure
|
Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies. |
Through 5 Years post-procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with technical success at the conclusion of the index procedure
大体时间:Through 5 Years post-procedure
|
Defined as the following:
|
Through 5 Years post-procedure
|
|
Major Adverse Events
大体时间:Through 5 Years post-procedure
|
Incidence of the following Major Adverse Events
|
Through 5 Years post-procedure
|
|
Incidence of procedure-related clinical utility measures
大体时间:Through 5 Years post-procedure
|
Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type. |
Through 5 Years post-procedure
|
|
Incidence of procedure-related complications
大体时间:Through 5 Years post-procedure
|
Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related. |
Through 5 Years post-procedure
|
|
Incidence of successful aneurysm treatment
大体时间:12 months post-implant
|
Successful aneurysm treatment is defined as:
|
12 months post-implant
|
|
Incidence of all-cause mortality
大体时间:Through 5 Years post-procedure
|
Rate of mortality attributed to any causality as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm-related mortality
大体时间:Through 5 Years post-procedure
|
Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm rupture
大体时间:Through 5 Years post-procedure
|
Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of secondary interventions.
大体时间:Through 5 Years post-procedure
|
Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System |
Through 5 Years post-procedure
|
|
Incidence of conversion to open surgical repair.
大体时间:Through 5 Years post-procedure
|
Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft occlusion (i.e., loss of patency)
大体时间:Through 5 Years post-procedure
|
Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition. |
Through 5 Years post-procedure
|
|
Incidence of device stenosis or kink
大体时间:Through 5 Years post-procedure
|
Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of loss of device integrity
大体时间:Through 5 Years post-procedure
|
Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
大体时间:Through 5 Years post-procedure
|
Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
大体时间:Through 5 Years post-procedure
|
Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of Type I, II, III, IV or V Endoleaks
大体时间:Through 5 Years post-procedure
|
Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab. |
Through 5 Years post-procedure
|
合作者和调查者
调查人员
- 研究主任:Gretchen Wild、Terumo Aortic
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.